Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study

被引:20
|
作者
Choe, Hun Jee [1 ,2 ]
Rhee, Eun-Jung [3 ]
Won, Jong Chul [4 ]
Park, Kyong Soo [1 ,2 ]
Lee, Won-Young [3 ]
Cho, Young Min [1 ,2 ]
机构
[1] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Div Endocrinol & Metab, Dept Internal Med,Sch Med, Seoul, South Korea
[4] Inje Univ, Sanggye Paik Hosp, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea
关键词
SENSING TECHNOLOGY; REAL-TIME; NUTRITION; RECOMMENDATIONS; MULTICENTER; MANAGEMENT; ADULTS; CARE;
D O I
10.2337/dc22-0764
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate the effects of patient-driven lifestyle modification using intermittently scanned continuous glucose monitoring (isCGM) in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS We conducted a 12-week, open-label, randomized controlled trial. A total of 126 participants were 1:1 randomized to either the intervention group (structured education + isCGM) or the control group (standard care with blood glucose monitoring). The Self-Evaluation Of Unhealthy foods by Looking at postprandial glucose (SEOUL) algorithm was developed and applied to aid structured education in guiding patients to follow healthy eating behavior depending on the postprandial glycemic response. The primary end point was the change in HbA(1c) level from baseline. RESULTS Implementation of the SEOUL algorithm with isCGM was associated with greater improvement in HbA(1c) than with standard care (risk-adjusted difference -0.50%, 95% CI -0.74 to -0.26, P < 0.001). Participants in the intervention group had a greater reduction in fasting blood glucose and body weight (-16.5 mg/dL, 95% CI -30.0 to -3.0, P = 0.017; -1.5 kg, 95% CI -2.7 to -0.3, P = 0.013, respectively). The score sum for the Korean version of the revised Summary of Diabetes Self-Care Activities Questionnaire increased in both groups but to a greater extent in the intervention group (mean difference 4.8, 95% CI 1.7-8.0, P = 0.003). No severe hyperglycemia or hypoglycemia was reported in either group of patients. CONCLUSIONS Patient-driven lifestyle modification primarily focused on eating behavior using isCGM effectively lowered HbA(1c) levels in patients with T2D.
引用
收藏
页码:2224 / 2230
页数:7
相关论文
共 50 条
  • [31] Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open-label, non-randomized pilot study
    Cannarella, Rossella
    Condorelli, Rosita A.
    Leanza, Claudia
    Garofalo, Vincenzo
    Aversa, Antonio
    Papa, Giuseppe
    Calogero, Aldo E.
    La Vignera, Sandro
    DIABETIC MEDICINE, 2024, 41 (01)
  • [32] Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial
    Visser, Margaretha M.
    Charleer, Sara
    Fieuws, Steffen
    De Block, Christophe
    Hilbrands, Robert
    Van Huffel, Liesbeth
    Maes, Toon
    Vanhaverbeke, Gerd
    Dirinck, Eveline
    Myngheer, Nele
    Vercammen, Chris
    Nobels, Frank
    Keymeulen, Bart
    Mathieu, Chantal
    Gillard, Pieter
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (02): : 96 - 108
  • [33] PATIENT PREFERENCES FOR CONTINUOUS GLUCOSE MONITORING DEVICES: A PRELIMINARY STUDY FROM PEOPLE LIVING WITH TYPE 2 DIABETES
    Lai, T.
    Whitley, H. P.
    Ngorsuraches, S.
    VALUE IN HEALTH, 2024, 27 (06) : S346 - S346
  • [34] Glucose Metabolic Responses to Colesevelam Alone or in Combination With Sitagliptin in Type 2 Diabetes Mellitus: A Randomized Open-Label Mechanism-of-Action Study
    Beysen, Carine
    Turner, Scott
    Deines, Kristin
    Tsang, Ellen
    Riiff, Tim
    Protasio, Joan
    Hellerstein, Marc
    DIABETES, 2013, 62 : A96 - A97
  • [35] Assessing Pharmacokinetic Interactions Between the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasemide in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Crossover Study
    Heise, Tim
    Mattheus, Michaela
    Woerle, Hans J.
    Broedl, Uli C.
    Macha, Sreeraj
    CLINICAL THERAPEUTICS, 2015, 37 (04) : 793 - 803
  • [36] Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial
    Haak, Thomas
    Hanaire, Helene
    Ajjan, Ramzi
    Hermanns, Norbert
    Riveline, Jean-Pierre
    Rayman, Gerry
    DIABETES THERAPY, 2017, 8 (01) : 55 - 73
  • [37] Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial
    Thomas Haak
    Hélène Hanaire
    Ramzi Ajjan
    Norbert Hermanns
    Jean-Pierre Riveline
    Gerry Rayman
    Diabetes Therapy, 2017, 8 : 55 - 73
  • [38] Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring
    He, Y. L.
    Foteinos, G.
    Neelakantham, S.
    Mattapalli, D.
    Kulmatycki, K.
    Forst, T.
    Taylor, A.
    DIABETES OBESITY & METABOLISM, 2013, 15 (12): : 1111 - 1119
  • [39] Effectiveness and Safety of the Intermittently Scanned Continuous Glucose Monitoring System FreeStyle Libre 2 in Patients with Type 2 Diabetes Treated with Basal Insulin or Oral Antidiabetic Drugs: An Observational, Retrospective Real-World Study
    Conti, Matteo
    Massari, Giulia
    Meneghini, Elena
    Pasquino, Bernadetta
    Agosti, Barbara
    Chinotti, Federica
    Pintaudi, Basilio
    Girelli, Angela
    Bertuzzi, Federico
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [40] Exenatide maintains glycemic control for 2 years in patients with type 2 diabetes: data from an ongoing, open-label study
    Ratner, RE
    Stonehouse, A
    Gao, HY
    Poon, T
    Kim, D
    DIABETOLOGIA, 2005, 48 : A288 - A289